Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity.
Pacmilimab induces antitumor responses comparable to those of the same dose of the parental antibody in mice bearing MC38 tumors[1].Pacmilimab accumulates in murine PD-L1-expressing tumors with minimal uptake in peripheral, non-cancerous lymphoid tissue, consistent with limited uptake in non-tumor PD-L1-expressing tissues and protection against autoimmunity[1].
References:
[1]. Naing A, et al. CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. J Immunother Cancer. 2021 Jul;9(7):e002447.